In the landscape of modern drug discovery, the traditional animal study has long been viewed as a linear process: an experiment is designed, a cohort of animals is selected, the study is conducted, data is gathered, and the remaining tissue samples are archived in storage, often never to be touched again. However, a seismic shift is underway. Propelled by the rapid adoption of digital pathology, researchers are transforming these "one-way street" experiments into vast, reusable data repositories. By mining existing tissue samples and digitizing histology, the scientific community is finding ways to extract deeper biological insights without the need for additional animal testing.
This evolution marks a transition from viewing pathology as a terminal endpoint—a single report generated by a pathologist—to viewing it as a dynamic, data-rich digital asset. As Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories, aptly notes, "Before, the pathology endpoint was just a report. Now, you have the digitized slide, which is pixels." These pixels are proving to be the key to unlocking a more efficient, ethical, and predictive future for pharmaceutical development.
A Chronology of the Digital Shift
The acceleration of digital pathology was born of necessity. During the COVID-19 pandemic, the physical isolation of pathologists from their traditional microscopes forced the industry to adopt remote digital workflows. What began as a temporary measure to maintain operations quickly demonstrated its inherent value.
- Pre-2020: Digital pathology was primarily a niche interest, largely confined to academic research or specific high-end diagnostics. Tissue slides were stored as physical glass, effectively "locking" the data away from advanced computational analysis.
- 2020–2022: The pandemic served as a catalyst. The widespread adoption of whole-slide imaging allowed pathology departments to digitize their workflows, turning physical slides into shareable, cloud-accessible digital images.
- 2022: The enactment of the FDA Modernization Act 2.0 signaled a major regulatory pivot, formally allowing for non-animal methods to support human clinical trial applications.
- 2024–2026: Leading organizations like Charles River Laboratories launched dedicated initiatives, such as the Alternative Methods Advancement Project, to institutionalize the use of digital tools and historical data to replace animal cohorts.
- Present Day: The industry is moving toward a future where "New Approach Methodologies" (NAMs) are not merely supplements to animal testing but the primary strategy for preclinical safety evaluation.
Mining the Archive: The Value of Legacy Tissue
One of the most potent weapons in the push to reduce animal reliance is the existing archive of formalin-fixed, paraffin-embedded (FFPE) tissue blocks. For decades, these blocks have been stored in laboratory basements, representing a "gold mine" of biological history.
When a drug’s mechanism of action is questioned after a study concludes, researchers have historically had to initiate new animal trials to gather fresh samples. Today, however, that is increasingly unnecessary. By returning to archived FFPE blocks, scientists can perform advanced molecular testing—such as proteomics or gene expression profiling—that provides retrospective answers to current questions.
The Organisation for Economic Co-operation and Development (OECD) bolstered this shift with its 2025 guidance, which outlines best practices for using preserved tissue in "omics" analysis. By maintaining the study context—ensuring that the tissue is linked to the original dosing, observational, and control data—researchers can effectively "run" a new experiment on old samples, thereby avoiding the sacrifice of new subjects.
Supporting Data: Efficiency Through Virtual Controls
A significant fraction of any toxicology study is dedicated to control animals—those that do not receive the drug but are handled in identical conditions to provide a baseline. In a massive industry where thousands of studies are performed annually, this equates to a staggering number of animals used for the sole purpose of comparison.
Charles River’s "virtual control group" initiative is designed to disrupt this necessity. By leveraging large datasets of historical control data, researchers can create digital baselines. If the historical data is robust and the study conditions are matched, these virtual groups can replace a significant portion of live control animals.
The challenge, as Dr. Zuraw points out, is ensuring data comparability. To avoid the risk of mistaking natural biological variance for a drug-induced effect, the industry is building large-scale, high-quality historical repositories. As these datasets grow, the statistical power of virtual controls increases, making them a reliable standard for safety assessments.
Official Responses and Regulatory Trajectory
The regulatory environment has shifted from cautious observation to proactive guidance. The U.S. Food and Drug Administration (FDA) has taken a leading role in this transition. Following the 2022 legislation, the agency has issued a series of updates, most notably in September 2026, aimed at modernizing preclinical testing requirements.
In April 2025, the FDA published a comprehensive roadmap detailing the path toward reducing animal testing. The plan adopts a phased approach:
- Phase I: Focus on monoclonal antibodies, where existing non-animal methods are most robust.
- Phase II: Expansion to other complex biologics.
- Phase III: Integration of new chemical entities.
The ultimate goal is to transition the industry over the next three to five years, moving animal studies from the "default" method to the "exception." This represents a fundamental change in the relationship between regulatory bodies and drug developers, where the adoption of digital tools and computational models is not only encouraged but expected.
Implications for Future Drug Discovery
The ripple effects of this digital transformation extend far beyond simple animal reduction. The integration of digital pathology with artificial intelligence (AI) is opening doors to predictive capabilities that were previously inconceivable.
Molecular Prediction from H&E Slides
Perhaps the most exciting frontier is the ability to predict molecular changes directly from standard hematoxylin and eosin (H&E) stained slides. AI models are being trained to recognize patterns in the pixel data of an H&E image that correlate with specific gene expression profiles or protein levels. This means that a standard diagnostic slide, once digitized, can provide a wealth of molecular data without the need for expensive, time-consuming lab assays.
The Rise of Virtual Staining
"Virtual staining" is another disruptive technology. By using algorithms to generate the appearance of stains on unstained tissue sections, researchers can skip the chemical staining process entirely. This not only reduces the use of toxic chemicals and reagents but also allows for multiple "virtual" stains to be applied to the same digital image, providing a multi-dimensional view of tissue biology that would be impossible with traditional physical methods.
A Snowball Effect
As labs invest in the infrastructure needed for these digital tools—scanners, high-performance computing, and data management software—a "snowball effect" is expected. The more digital data that is created, the more valuable the archive becomes. Researchers can query these datasets with new algorithms, asking questions that the original researchers never considered.
"You still need enough early adopters to generate precedent," Dr. Zuraw emphasizes. The current vanguard of researchers, pathologists, and regulatory scientists are the ones doing the "troubleshooting," establishing the protocols that will eventually become industry standard.
Conclusion: The Path Forward
The transition toward a digital-first approach in pathology represents one of the most significant advancements in preclinical research in the last century. By maximizing the utility of every animal used in research and turning archived tissue into a living library of biological information, the pharmaceutical industry is demonstrating that ethical advancement and scientific rigor are not mutually exclusive.
As we look toward 2030, the vision is clear: a pharmaceutical development process defined by computational speed, data-driven accuracy, and a drastically reduced reliance on animal models. The "old" tissue sitting in storage is no longer just a relic of the past; it is the fuel for the next generation of life-saving medical discoveries. Through the combination of virtual control groups, AI-driven molecular prediction, and a supportive regulatory framework, the digital pathology revolution is ensuring that the future of drug discovery is both smarter and more humane.
About the Author
